An overview on anti-tubulin agents for the treatment of lymphoma patients.
Antibody drug conjugates
Dolastatins
Epothilones
Maytansine
Taxanes
Vinca alkaloids
Journal
Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
03
2020
accepted:
14
04
2020
pubmed:
20
4
2020
medline:
28
5
2021
entrez:
20
4
2020
Statut:
ppublish
Résumé
Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the literature on classic and more recent anti-tubulin agents, providing an insight into their mechanisms of action and their use in the treatment of lymphoma.
Identifiants
pubmed: 32305312
pii: S0163-7258(20)30080-2
doi: 10.1016/j.pharmthera.2020.107552
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Tubulin
0
Tubulin Modulators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107552Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Anastasios Stathis: institutional research funds from: Bayer, ImmunoGen, Merck, Pfizer, Novartis, Roche, MEI Pharma, ADC-Therapeutics; travel grant from AbbVie and PharmaMar. Francesco Bertoni: institutional research funds from Acerta, ADC Therapeutics, Bayer AG, Cellestia, CTI Life Sciences, EMD Serono, Helsinn, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics 1, Nordic Nanovector ASA, Oncology Therapeutic Development, PIQUR Therapeutics AG; consultancy fee from Helsinn, Menarini; expert statements provided to HTG; travel grants from Amgen, Astra Zeneca, Jazz Pharmaceuticals, PIQUR Therapeutics AG. The other Authors have nothing to disclose.